SLC5A2 and atrial fibrillation: Here, we examined whether empagliflozin, an SGLT2-i, suppresses mitochondrial ROS generation and mitigates inflammatory as well as fibrotic remodeling of the atria, which could potentially result in reduced AF inducibility.